Niloufar Ebrahimi

Dr. Niloufar Ebrahimi

Medicine | Nephrology, Loma Linda University Medical Center, Loma Linda, California, USA
orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2024 in Kidney360
Verified
Journal Article
Open access
Niloufar EbrahimiNiloufar Ebrahimi
Niloufar Ebrahimi
PGPranav Garimella
Pranav Garimella
FCFouad Chebib
Fouad Chebib
MSMatthew A. Sparks
Matthew A. Sparks
Edgar LermaEdgar Lerma
Edgar Lerma
SNSayna Norouzi
Sayna Norouzi
Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder marked by the development of cysts in the kidneys and other organs, leading to diverse clinical manifestations, including kidney failure. The psychological burden of ADPKD is substantial, with significant contributors including pain, daily life disruptions, depression, anxiety, and the guilt associated with transmitting ADPKD to offspring. This review details the psychological impacts of ADPKD on patients, addressing how they navigate physical and emotional challenges, including pain management, genetic guilt, mood disorders, and disease acceptance. This review also underscores the need for comprehensive research into the psychological aspects of ADPKD, focusing on the prevalence and contributing factors of emotional distress and identifying effective strategies for managing anxiety and depression. Furthermore, it highlights the importance of understanding the diverse factors that influence patients' quality of life and advocates for holistic interventions to address these psychological challenges.

1 January 2025 in Glomerular Diseases
Verified
Journal Article
Open access
MVMehrbod Vakhshoori
Mehrbod Vakhshoori
GHGiv Heidari-Bateni
Giv Heidari-Bateni
RMRoy O. Mathew
Roy O. Mathew
AAAmir Abdipour
Amir Abdipour
NDNoha S. Daher
Noha S. Daher
SNSayna Norouzi
Sayna Norouzi
Introduction: Systemic lupus erythematous (SLE) is known to be associated with cardiovascular events (CVEs). However, the incidence of CVE has not been thoroughly investigated in lupus nephritis (LN) patients. In this meta-analysis, we aimed to assess the incidence of CVE in patients with LN. Methods: We performed a literature search in PubMed, Scopus, and Web of Science database for studies reporting CVE (myocardial infarction [MI], heart failure, cerebrovascular accident [CVA] [i.e., ischemic or hemorrhagic stroke or transient ischemic attack], any cardiovascular- or cerebrovascular-related disease or death) in patients with LN. In addition, subgroup analyses were conducted according to geographical locations and kidney disease status. We also separately reported the incidence rate of MI, CVA, and cardiovascular- or cerebrovascular-related deaths, with CVE and MI risk in patients with LN. Results: Twenty-one records, encompassing 29,489 subjects, were included. The overall CVE incidence was 9% (95% confidence interval [CI]: 6–12%). Specifically, the incidence of MI (8 studies, n = 5,735), CVA (9 studies, n = 6,053), and mortality attributed to any cardiovascular or cerebrovascular disease (10 studies, n = 26,511) were 4% (95% CI: 2–7%), 4% (95% CI: 2–7%), and 5% (95% CI: 3–7%), respectively. Geographically, patients residing in Asia exhibited a lower incidence of CVE (2.3%, 95% CI: 1.6–3.3%) compared to those residing in North America (10.1%, 95% CI: 5.7–17.2%) and Europe (13.3%, 95% CI: 7.6–22.4%). Patients with LN had higher risk of CVE compared to SLE subjects (odds ratio: 1.18, 95% CI: 1.03–1.34, p = 0.014). Conclusion: CVE occurrence among individuals with LN is significant, and this disease entity increases CVE risk, highlighting the importance of implementing early therapeutic interventions to prevent poor outcomes.

28 October 2024 in Kidney International Reports
Verified
Journal Article
Open access
Niloufar EbrahimiNiloufar Ebrahimi
Niloufar Ebrahimi
RGRichard J. Glassock
Richard J. Glassock
ZGZohreh Gholizadeh Ghozloujeh
Zohreh Gholizadeh Ghozloujeh
MHMohamed Hassanein
Mohamed Hassanein
MNMelin Narayan
Melin Narayan
SNSayna Norouzi
Sayna Norouzi

2 July 2025 in Transfusion and Apheresis Science
Verified
Journal Article
Closed access
MGMohadese Golsorkhi
Mohadese Golsorkhi
Niloufar EbrahimiNiloufar Ebrahimi
Niloufar Ebrahimi
SKShahram Kordasti
Shahram Kordasti
SNSayna Norouzi
Sayna Norouzi
APAmir Abdi Pour
Amir Abdi Pour

19 February 2025 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
Niloufar EbrahimiNiloufar Ebrahimi
Niloufar Ebrahimi
VHVince Ha
Vince Ha
WWWilliam Whittier
William Whittier
OEOrhan Efe
Orhan Efe
Andreas KronbichlerAndreas Kronbichler
Andreas Kronbichler
SNSayna Norouzi
Sayna Norouzi
An abstract is unavailable. This article is available as a PDF only.

1 January 2024 in Journal of Investigative Medicine High Impact Case Reports
Verified
Journal Article
Open access
Niloufar EbrahimiNiloufar Ebrahimi
Niloufar Ebrahimi
MBMaha Al Baghdadi
Maha Al Baghdadi
CZCraig W. Zuppan
Craig W. Zuppan
DRDaniel K. Rogstad
Daniel K. Rogstad
APAmir Abdi Pour
Amir Abdi Pour
BK virus (BKV) is a small DNA virus, a member of the polyomavirus family, that causes an opportunistic infection in immunocompromised patients, especially kidney transplant patients. This virus establishes a lifelong infection in most of the population, and once it reactivates in an immunocompromised state, leads to BKV nephropathy. This review seeks to assess the correlation between severe immunosuppression, evident by low CD4 cell counts in HIV-positive patients, and the reactivation of BKV, causing nephropathy. A literature review was conducted, extracting, and analyzing case reports of HIV-positive patients showing correlations between their degree of immunosuppression, as evidenced by their CD4 counts, and the degree of BKV infectivity, confirmed by kidney biopsy. A total of 12 cases of BKV nephropathy in HIV-infected patients were reviewed. A common finding was the presence of profound immunosuppression, with most patients having CD4 counts ≤50 cells/ mm3. A substantial number also had comorbid malignancies, with some undergoing chemotherapy, potentially increasing the risk of BKV reactivation. In addition to the HIV status and malignancies, other risk factors for BKV reactivation included older age, male gender, diabetes mellitus, Caucasian race, and ureteral stent placement. BKV nephropathy in HIV patients with native kidneys is closely correlated with severe immunosuppression. Although therapeutic strategies exist for post-transplant patients, aside from the treatment of HIV with highly active anti-retroviral therapy (HAART), which potentially helps with clearing BKV by increasing CD4 count, there is no definitive treatment for a native kidney BKV nephropathy in patients with AIDS. The complexity of the cases and severity of comorbidities indicate the need for further research to develop therapeutic strategies tailored to this population.